Autolus Therapeutics Plc(NASDAQ) AUTL

Market Cap$622.82M

Since IPO (2018)-91%

5 Year-66%

1 Year+49%

1 Month+60%

Premium Feature

Moneyball Superscore

69/100

$2.33

-1.48%

-0.03Today

After hours$2.34+$0.01 (+0.43%)

Autolus Therapeutics Plc last closing stock price
Metric	Price	Date
Last close	USD 2.34	2026-08-28

Autolus Therapeutics Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.9%	USD 2.41	2026-08-21
1 month	+60.27%	USD 1.46	2026-07-29
3 month	+25.13%	USD 1.87	2026-05-29
Year to date	+17.59%	USD 1.99	2025-12-31
1 year	+49.04%	USD 1.57	2025-08-28
3 year	-29.09%	USD 3.30	2023-08-29
5 year	-65.54%	USD 6.79	2021-08-27
Since inception	-90.64%	USD 25.00	2018-06-22

Autolus Therapeutics Plc Financials at a Glance

Market Cap

$622.82M

Revenue (TTM)

$117.35M

Net Income (TTM)

-$280.03M

EPS (TTM)

-$1.05

P/E Ratio

-2.23

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$2.33

Volume

1,436,887.197

Open

$2.35

Price

$2.33

Volume

1,436,887.197

Open

$2.35

Previous Close

$2.34

Daily Range

$2.28 - $2.36

52-Week Range

$1.18 - $2.58

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$2.33

Volume

1,436,887.197

Open

$2.35

Previous Close

$2.34

Daily Range

$2.28 - $2.36

52-Week Range

$1.18 - $2.58

Estimated Earnings Date

Nov 11, 2026

AUTL News

Scientists in a lab, monitor, microscope

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

David HaenOct 9, 2019

AUTL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Autolus Therapeutics Plc

Autolus Therapeutics plc makes treatments that help the immune system fight cancer. These therapies reprogram a patient's own cells to kill diseased cells. The company helps patients with serious blood cancers and autoimmune diseases.

Engineering Better Immune Cells

AUCATZYL: Approved therapy for adults with a type of blood cancer that has returned or failed other treatments.
Obe-cel Pipeline: Group of experimental programs testing the flagship treatment for pediatric leukemia, lupus, and multiple sclerosis.
AUTO8: Product candidate being tested in clinical trials for light-chain amyloidosis, a rare protein buildup disorder.
AUTO4: Programmed therapy designed to target specific markers to treat a form of lymphoma.

Scaling Up and Trimming Down

Launched AUCATZYL in the United Kingdom in Jan. 2026 following its United States market entry in Jan. 2025.
Secured a senior credit facility for up to $250 million from Perceptive Advisors in July 2026.
Implemented a workforce reduction plan in April 2026 to cut total staff by 13%.
Formed strategic collaborations with Blackstone and BioNTech to support product development and share future revenue.

What Makes Autolus Different?

Autolus uses proprietary technology to program a patient's white blood cells, called T cells, to better recognize and destroy cancer. The company controls its production through a specialized manufacturing site called the Nucleus facility to ensure quality for personalized treatments.

A Look at the Books

Product revenue reached $45.7 million for the three-month period ended June 30, 2026, up 118% year over year.
Cost of sales as a percentage of revenue dropped to 45% for the three-month period ended June 30, 2026.
Cash and cash equivalents totaled $171.4 million as of June 30, 2026.
Net loss was $39.1 million for the three-month period ended June 30, 2026, down 18% year over year.

Evolution into a Commercial Business

Autolus has transitioned from a research entity into a commercial-stage business with active sales in two major global markets. The company's recent focus on operational efficiency and pipeline expansion marks a significant shift in its long-term growth strategy.

AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

752

CEO

Christian Martin Itin, PhD

Website

www.autolus.com

Headquarters

London, GL W12 7FP, GB

AUTL Financials

Key Financial Metrics (TTM)

Gross Margin

15.66%

Operating Margin

-210.76%

Net Income Margin

-238.62%

Return on Equity

-178.58%

Return on Capital

-53.13%

Return on Assets

-56.77%

Earnings Yield

-44.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$622.82M

Shares Outstanding

266.16M

Volume

1.44M

Avg. Volume

1.91M

Financials (TTM)

Gross Profit

$18.38M

Operating Income

-$247.33M

EBITDA

-$221.40M

Operating Cash Flow

-$225.61M

Capital Expenditure

-$11.84M

Free Cash Flow

-$237.45M

Cash & ST Invst.

$201.63M

Total Debt

$83.51M

Autolus Therapeutics Plc Performance Analysis

Autolus Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 6,190,177	310.8%
2023	2023-12-31	USD 1,704,582	-72.5%
2024	2024-12-31	USD 10,124,258	493.9%
2025	2025-12-31	USD 75,564,172	646.4%

Autolus Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	1.3%
Q4	2025-12-31	14.4%
Q1	2026-03-31	8.1%
Q2	2026-06-30	74.3%

Autolus Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.57	-20.6%
2023	2023-12-31	USD -1.20	-23.2%
2024	2024-12-31	USD -0.87	-28.1%
2025	2025-12-31	USD -1.08	25.2%

Autolus Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-66.7%
Q4	2025-12-31	-13.3%
Q1	2026-03-31	20.6%
Q2	2026-06-30	44.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$45.69M

+118.4%

Gross Profit

$25.22M

+816.1%

Gross Margin

55.20%

N/A

Market Cap

$622.82M

N/A

Market Cap/Employee

$828.22K

N/A

Employees

752

N/A

Net Income

-$39.11M

+18.4%

EBITDA

-$33.81M

+21.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$201.63M

-55.6%

Total Debt

$83.51M

+29.4%

Accounts Receivable

$44.39M

-43.5%

Inventory

$33.43M

+39.6%

Long Term Debt

$77.72M

+26.9%

Short Term Debt

$5.79M

+76.7%

Return on Assets

-56.77%

N/A

Return on Invested Capital

-58.27%

N/A

Free Cash Flow

-$25.98M

+67.5%

Operating Cash Flow

-$25.07M

+65.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AURAAura Biosciences, Inc.

AURAAura Biosciences, Inc.$7.40-3.90%

ANNXAnnexon, Inc.

ANNXAnnexon, Inc.$4.97-5.33%

BNTCBenitec Biopharma Inc.

BNTCBenitec Biopharma Inc.$12.47-1.58%

RCKTRocket Pharmaceuticals, Inc.

RCKTRocket Pharmaceuticals, Inc.$3.86+6.63%

RAPTRAPT Therapeutics, Inc.

RAPTRAPT Therapeutics, Inc.$58.01+0.00%

SLDBSolid Biosciences Inc.

SLDBSolid Biosciences Inc.$9.77-3.55%

NMRANeumora Therapeutics, Inc. Common Stock

NMRANeumora Therapeutics, Inc. Common Stock$1.39-6.08%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$217.55-0.05%

PCGPG&E

PCGPG&E$16.60-0.08%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.45-0.03%

IRENIren

IRENIren$35.45-0.13%

INTCIntel

INTCIntel$89.47-0.03%

NUNu Holdings

NUNu Holdings$14.30-0.04%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.90-0.03%

Questions About AUTL

What is the current price of Autolus Therapeutics Plc?

Autolus Therapeutics Plc is trading at $2.34 per share.

What is the 52-week range for Autolus Therapeutics Plc?

Over the past 52 weeks, Autolus Therapeutics Plc has traded between $1.18 and $2.58.

How much debt does Autolus Therapeutics Plc have?

As of the most recent reporting period, Autolus Therapeutics Plc reported total debt of $367.81M.

How much cash does Autolus Therapeutics Plc have on hand?

Autolus Therapeutics Plc reported $172.91M in cash and cash equivalents in its most recent financial results.

What is Autolus Therapeutics Plc’s dividend yield?

Autolus Therapeutics Plc does not currently have a dividend yield.

Autolus Therapeutics Plc(NASDAQ) AUTL

Autolus Therapeutics Plc Financials at a Glance

AUTL News

Why Autolus Therapeutics Stock Is Crashing Today

Why Autolus Therapeutics Stock Jumped 25% Today

Here's Why Autolus Therapeutics Is Surging Today

Why Autolus Therapeutics Stock Skyrocketed Today

Why Autolus Therapeutics Shares Are Plunging Today

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

AUTL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Autolus Therapeutics Plc

Engineering Better Immune Cells

Scaling Up and Trimming Down

What Makes Autolus Different?

A Look at the Books

Evolution into a Commercial Business

AUTL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Autolus Therapeutics Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AUTL

What is the current price of Autolus Therapeutics Plc?

What is the 52-week range for Autolus Therapeutics Plc?

How much debt does Autolus Therapeutics Plc have?

How much cash does Autolus Therapeutics Plc have on hand?

What is Autolus Therapeutics Plc’s dividend yield?

Premium Investing Services